PROGRAM MENU

EDUCATIONAL PROGRAM

PRE-SUMMIT WORKSHOPS

SATELLITE SYMPOSIA


Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2026 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.


  Wed - Mar 18      Thu - Mar 19      Fri - Mar 20      Sat - Mar 21   

FRIDAY, MARCH 20

7:00 - 8:00 AM
SATELLITE SYMPOSIUM
ADVANCES IN VON WILLEBRAND DISEASE: FROM GENETICS TO PROPHYLAXIS (SPONSORED BY OCTAPHARMA)
B115-116

This symposium will highlight current and emerging strategies to improving the diagnosis and management of von Willebrand disease (VWD) from genetics to long-term prophylaxis The program will begin with address advances in VWD diagnostics, focusing on the clinical utility of VWF genotyping. The investigator-initiated VUS study will be presented, evaluating whether VWF genotyping improves diagnostic accuracy, variant interpretation, treatment decisions, bleeding-related quality of life, and family testing. The symposium will also explore iron deficiency as an important and often under-recognized comorbidity in VWD. The final part of the symposium will focus on prophylactic treatment strategies in VWD, reviewing data from the WIL-31 and WIL-33 studies demonstrating the effectiveness of VWF concentrate prophylaxis across VWD subtypes and age groups. Planned US-based cost-effectiveness analysis and of concepts of personalized prophylaxis, including the design and rationale of the POPPK study, will be also introduced. The session will be chaired by Veronica Flood, with faculty Robert Sidonio and Jill Johnsen.



JOINT HEALTH AND PHYSICAL ACTIVITY IN PATIENTS WITH HEMOPHILIA A: PANEL DISCUSSION AND TRIVIA WITH EXPERTS (SPONSORED BY GENENTECH)
B113-114

Are you ready to compete? Join us in testing your knowledge on the efficacy and safety data for the first subcutaneous prophylaxis treatment for hemophilia A. This gameshow will highlight pivotal clinical trial data and safety as well as information on joint health and physical activity in patients with hemophilia A. There will be a discussion on experts clinical practice experiences and insights.


7:00 - 8:00 PM
EVENT/OTHER
REGISTRATION
Oregon Ballroom Lobby

8:15 - 9:45 AM
LABORATORY
CHALLENGES IN ANALYZING COAGULATION PARAMETERS--NEW SOLUTIONS TO OLD PROBLEMS?
Chair/Organizer: Kristi Smock, Martha Eva Viveros
Oregon Ballroom 204


8:15
GUIDANCE FOR APPLYING, VERIFYING, AND/OR VALIDATING AI IN THE CLINICAL LABORATORY SETTING
JANSEN SEHEULT.


9:07
HOW NEW GENERATION VWF ASSAYS HAVE CHANGED VWF DIAGNOSIS
CHRISTOPHER NG.

8:15 - 9:45 AM
HEMOSTASIS
CLINICAL CONSIDERATIONS: AGING WITH A BLEEDING DISORDER
Chair/Organizer: Dawn Rotellini, Caroline Kruse
Oregon Ballroom 203


8:15
BONE HEALTH, CONSIDERATIONS AS OUR PATIENTS AGE
CRAIG KESSLER.


8:45
CARDIOVASCULAR CONSIDERATIONS & DRUG INTERACTIONS IN THE CARE OF BLEEDING DISORDERS
JONATHAN ROBERTS.


9:15
PSYCHOSOCIAL CONSIDERATIONS IN AGING PATIENTS WITH BLEEDING DISORDERS
KATHALEEN SCHNUR.

8:15 - 9:45 AM
THROMBOSIS / BASIC SCIENCE
DON'T FORGET THE KIDNEYS! RENAL CONSIDERATIONS IN THROMBOSIS PATHOLOGY AND MANAGEMENT
Chair/Organizer: Jori May, Tara Lech
Oregon Ballroom 201


8:15
BASIC SCIENCE PERSPECTIVE ON THROMBOSIS, DOACS, AND THE KIDNEY
BRYCE KERLIN.


8:45
MICROTHROMBI AND COMPLEMENT MEDIATED RENAL DISEASE
CHRISTOPH LICHT.


9:15
CLINICAL PERSPECTIVE ON ANTICOAGULATION WITH DOACS IN KIDNEY DISEASE
MARISA BATTISTELLA.

9:45 - 10:30 AM
POSTERS/EXHIBITS/BREAK
POSTERS/EXHIBITS/BREAK (click to view)
Exhibit Hall A


A1. ANTICOAGULATION CLINICS


400
COMPARING WARFARIN DOSE DECISION MAKING BEFORE AND AFTER TRANSITION TO PATIENT SELF-MANAGEMENT
JACK M. LAWRENCE1, GEOFFREY D. BARNES2, KATELYN W. SYLVESTER3, LINH CHAN4, SARA R. VAZQUEZ5, AUBREY E. JONES1, 5, SPENCER J. GILBERT1, 5, DANIEL M. WITT1, 5. 1University of Utah College of Pharmacy, Salt Lake City, UT, USA. 2University of Michigan, Ann Arbor, MI, USA. 3Brigham and Women's Hospital, Boston, MA, USA. 4Veterans Affairs Loma Linda Healthcare System, Loma Linda, CA, USA. 5University of Utah Health Thrombosis Service, Salt Lake City, UT, USA


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS


403
ICOAGLAB MEASURES COMPREHENSIVE COAGULATION PROFILES WITHIN MINUTES IN CARDIAC INTENSIVE CARE PATIENTS
DANIEL HOARE1, JAY SAGGU2, RUSUL AL-ANI2, KRISTEN WARREN2, ANIKET JOSHI1, CHRISTOPH NABZDYK2, SEEMANTINI NADKARNI1. 1Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 2Division of Anesthesiology, Perioperative and Pain Medicine, Harvard Medical School, Brigham and Womena, Boston, MA, USA


404
THROMBOTIC COMPLICATIONS IN SICKLE CELL ANEMIA
BHAKTI SINGH1, NEHA THOMAS1, ATUL LADDU1, FAKIHA SIDDIQUI2, JAWED FAREED2. 1Global Thrombosis Forum, Suwanee, GA, USA. 2Loyola University, Chicago, IL, USA


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


405
SEX AND AGE-BASED EVALUATION OF A NEWLY FORMULATED INTRANASAL DDAVP COMPARED WITH INTRANASAL DDAVP AND SUBCUTANEOUS DDAVP IN TYPE 1 VON WILLEBRAND DISEASE
SANJAY AHUJA1, SWETA GUPTA1, MAGDALENA LEWANDOWSKA1, JENNIFER MAAHS1, SONIA NASR2, AMY SHAPIRO1. 1Innovative Hematology, Indiana Hemophilia a Thrombosis Center, Indianapolis, IN, USA. 2GLOVAL LLC, Broomfield, CO, USA


406
CYTOKINE RELEASE SYNDROME AND THROMBOSIS RISK AFTER CAR-T THERAPY
COURTNEY CRAWFORD1, PARMIS SAHRAPIMA1, JOSEPH SHATZEL2, 3, CORINNE LAVASSEUR2, 3. 1Department of Internal Medicine, Oregon Health and Sciences University, Portland, OR, USA, Portland, OR, USA. 2Division of Hematology and Medical Oncology, Oregon Health and Sciences University, Portland, OR, USA, Portland, OR, USA. 3Knight Cancer Institute, Portland, OR, USA


407
DEEP VEIN THROMBOSIS FOLLOWING CALF HEMATOMA IN A PEDIATRIC PATIENT WITH FACTOR VII DEFICIENCY
GRACE HAUSE, OMS-II1, FRED LOEFFLER, PT, DPT, LAT, ATC, CLT2, STEPHANIE GARRISON, NP3, NIHAL BAKEER, MD3, 4, 5, EMAN ABDELGHANI, MD3. 1Marian University Wood College of Osteopathic Medicine, Indianapolis, IN, USA. 2Physical Therapy, Indiana Hemophilia and Thrombosis Center, Innovative Hematology Inc, Indianapolis, IN, USA. 3Innovative Hematology Inc. / Indiana Hemophilia and Thrombosis Center (IHI/IHTC), Indianapolis, IN, USA. 4Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 5Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA, USA


408
MIM8 PROPHYLAXIS IN ADULTS AND ADOLESCENTS WITH HEMOPHILIA A: 52-WEEK EFFICACY AND SAFETY OUTCOMES FROM THE PHASE 3 FRONTIER2 STUDY
STEVEN R LENTZ1, ABY ABRAHAM2, CIHAN AY3, ANTHONY KC CHAN4, VICTOR JIMACNEZ-YUSTE5, JOHANNES OLDENBURG6, MARIA ELISA MANCUSO7, 8, JOHNNY MAHLANGU9, TADASHI MATSUSHITA10, LIZE VAN VULPEN11, RENCHI YANG12, AMALIE RHODE HACGH NIELSEN13, ILGIZ RAKHMATULLIN13, EMILY WATERS14, PRATIMA CHOWDARY15, MARIA LAGE14. 1Department of Internal Medicine, University of Iowa, Iowa City, IA, USA. 2Department of Clinical Haematology, Christian Medical College, Vellore, Tamil Nadu, India. 3Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria. 4McMaster Childrena, Hamilton, ON, Canada. 5Hospital Universitario La Paz, Universidad AutA³noma de Madrid, Madrid, Spain. 6The Institute of Experimental Hematology and Transfusion Medicine, UniversitActsklinikum Bonn, Bonn, Germany. 7Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. 8Humanitas University, Pieve Emanuele, Milan, Italy. 9Department of Molecular Medicine and Haematology, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa. 10Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan. 11Center for Benign Haematology, Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht, Netherlands. 12Thrombosis and Hemostasis Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. 13Novo Nordisk A/S, SAcborg, Denmark. 14Novo Nordisk Inc, Plainsboro, NJ, USA. 15Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, Department of Haematology, University College London, London, United Kingdom


409
VISUALIZATION AND CHARACTERIZATION OF VON WILLEBRAND MULTIMER BANDING PATTERNS IN ACQUIRED VON WILLEBRAND SYNDROME:A RETROSPECTIVE STUDY
SERENA D. NAVITSKAS1, FATIMA SHABA2, RAJIV K. PRUTHI1, 2, DONG CHEN1, MEERA SRIDHARAN1, 2. 1Department of Laboratory Medicine, Rochester, MN, USA. 2Department of Medicine, Rochester, MN, USA


410
EMICIZUMAB FOR SEVERE VON WILLEBRAND DISEASE (VWD): THE EMIVWD STUDY ENROLLMENT 2026
JONATHAN C. ROBERTS1, 2, MAY CHIEN3, SWETA GUPTA4, ANGELA WEYAND5, REBECCA KRUSE-JARRES6, ERIN COCKRELL7, FERNANDO F. CORRALES-MEDINA8, VANESSA SALINAS9, SHANNON L. CARPENTER10, ERIN ESPINOZA11, ABDULRAHEEM YACOUB12, DAYNA LENSKI1, SARA MALIK1, SARAH KREITZER1, MICHAEL D. TARANTINO1, 2. 1Bleeding a Clotting Disorders Institute, Dills Family Foundation Center for Research at BCDI, Peoria, IL, USA. 2Departments of Pediatrics and Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, USA. 3Stanford University, Stanford, CA, USA. 4Innovative Hematology, Indiana Hemophilia and Thrombosis Center, Indianapoils, IN, USA. 5University of Michigan Medicine, Ann Arbor, MI, USA. 6Washington Center for Bleeding Disorders, Seattle, WA, USA. 7St. Josepha, Tampa, FL, USA. 8Division of Pediatric Hematology-Oncology, University of Miami Miller School of Medicine, Miami, FL, USA. 9Center for Inherited Blood Disorders, Orange, CA, USA. 10Childrena, Kansas City, MO, USA. 11Tri-Health Cancer Institute, Cincinnati, OH, USA. 12University of Kansas Cancer Center, Westwood Kansas, KS, USA


411
HEMOPHILIA LIFE STAGES AND CHANGES GLOBAL SURVEY OF PEOPLE WITH HEMOPHILIA, CAREGIVERS, AND HEMATOLOGISTS: DATA FROM UNITED STATES AND CANADIAN RESPONDENTS
MARK W. SKINNER1, 2, KIM ISENBERG3, PAMELA WILTON4, ANDREW WILSON5, LYNN MALEC6, KYRIE SMITH-JONES5. 1Institute for Policy Advancement, Ltd, Washington, DC, USA. 2Assistant Clinical Professor, McMaster University, Hamilton, ON, Canada. 3Sanofi, Minneapolis, MN, USA. 4Canadian Hemophilia Society, Montreal, QC, Canada. 5Sanofi, Cambridge, MA, USA. 6Versiti Blood Research Institute Associate Professor, Division of Hematology and Oncology, Departments of Medicine and Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA


412
EVALUATION OF D-DIMER IN PATIENTS WITH END-STAGE RENAL DISEASE
SANA VERMA1, KEERTI CHAKRAVARTHY1, FAKIHA SIDDIQUI2, VINOD BANSAL2, JAWED FAREED2. 1Global Thrombosis Forum, Suwanee, GA, USA. 2Loyola University, Chicago, IL, USA


A7. PATHOPHYSIOLOGY OF THROMBOSIS


413
VENOUS THROMBOEMBOLISM OUTCOME-ONLY QUALITY MEASURES FAIL TO PROVIDE ACTIONABLE INFORMATION ABOUT PREVENTION PRACTICES
BRANDYN D. LAU1, 2, 3, 4, MICHAEL B. STREIFF1, 2, DAURYNE L. SHAFFER5, PEGGY S. KRAUS5, ELLIOTT R. HAUT1, 2, 3, 4. 1Johns Hopkins School of Medicine, Baltimore, MD, USA. 2Armstrong Institute for Patient Safety and Quality, Baltimore, MD, USA. 3Welch Center for Prevention, Epidemiology, and Clinical Research, Baltimore, MD, USA. 4Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 5Johns Hopkins Hospital, Baltimore, MD, USA


A8. ANTITHROMBOTIC THERAPY


414
ONCOLOGY PROVIDER PRACTICES AND PERSPECTIVES ON AMBULATORY THROMBOPROPHYLAXIS
CHRISTINA DI CARLO1, ZAYYA ZENDO1, BEATRICE FLORIS2, MARIA CHAUDHRY2, MOE EL-ZEIN2, FATIMA HAMAD2, CRISTIAN IANNICELLO2, ANDREA CERVI1, 3. 11Schulich School of Medicine a Dentistry, London, ON, Canada. 2University of Windsor, Windsor, ON, Canada. 3Department of Medical Oncology, Windsor Regional Cancer Center, Windsor, ON, Canada


415
MECHANISTIC POPULATION PK/PD MODELING OF FACTOR XI-TARGETING MONOCLONAL ANTIBODIES REGN7508CAT AND REGN9933A2 IN HEALTHY VOLUNTEERS: A FOUNDATION FOR DOSE SELECTION AND CLINICAL TRANSLATION
OLEG MILBERG1, HISHAM ABDALLAH1, RACHEL KUDGUS LOKKEN2, ROBERT DINGMAN1, KAROLINE A. MEAGHER1, MICHAEL E. BURCZYNSKI1, ETHAN MARIN1, AARON KITHCART1, DAVID E. GUTSTEIN1. 1Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA. 2Allucent, Cary, NC, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


416
APPROPRIATENESS OF HEPARIN-INDUCED THROMBOCYTOPENIA TESTING AND ASSOCIATED PATIENT OUTCOMES ACROSS INTERMOUNTAIN HEALTH
AMINAH R. ALTALHI, CLINTON S. ANDERSON, SCOTT C. WOLLER, DAVE S. COLLINGRIDGE, GABRIEL V. FONTAINE. Intermountain Health, Salt Lake, UT, USA


417
ADDRESSING TRAVEL BARRIERS IN HEMOPHILIA CARE: FROM NEEDS ASSESSMENT TO REGIONAL SATELLITE CLINIC IMPLEMENTATION
SIDNEY GLASS, ELIZABETH HUNT, ERIKA MARTIN. Virginia Commonwealth University, Richmond, VA, USA

10:30 - 11:30 AM
SHORT TALKS
SHORT TALKS - ANTICOAGULATION THERAPY: BEST PRACTICES AND COMPLICATION MANAGEMENT
Chair/Organizer: Gabe Fontaine, Gordon Minaker
Oregon Ballroom 203


10:30
HEMATOLOGIC EVIDENCE OF IRON DEFICIENCY COMMON BELOW FERRITIN 50 NG/ML
LISA BAUMANN KREUZIGER1, 2, RYAN HANSON3, JULIE KOLINSKI2, NATHAN LEDEBOER2, ALEXANDRA HARRINGTON2, ROBERT NERENZ2. 1Versiti Blood Research Institute, Milwaukee, WI, USA. 2Medical College of Wisconsin, Milwaukee, WI, USA. 3Froedtert Hospital, Milwaukee, WI, USA


10:42
MANAGING NEONATAL CENTRAL VENOUS CATHETER-RELATED THROMBOSIS: A ROLE FOR RIVAROXABAN
MOLLY C EASTERLIN1, MOHIT MEHRA1, XINWEN LI1, WENDY LEUNG1, ASHWINI LAKSHMANAN2, SHAHAB NOORI1, PHILIPPE FRIEDLICH1, JOSEPH MILLER1, JULIE JAFFRAY3. 1University of Southern California/Children's Hospital Los Angeles, Los Angeles, CA, USA. 2Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA. 3University of California, San Diego/Rady Childrena, San Diego, CA, USA


10:54
VALIDATION OF ANTICOAGULANT NEUTRALIZING AGENTS FOR LUPUS ANTICOAGULANT TESTING: COMBINED EVALUATION OF DOAC-STOP AND HEPZYME(THSNAELIZABETH VAN COTT TRAVEL AWARDEE)
GORDON MINAKER1, STEVEN WONG2, 3, HAMISH NICOLSON2, 3. 1Department of Internal Medicine, University of British Columbia, Vancouver, BC, Canada. 2Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada. 3Providence Health Care, St. Paula, Vancouver, BC, Canada


11:06
INCIDENTAL PULMONARY EMBOLISM: WHEN TREATMENT MAY BE WORSE THAN THE DIAGNOSIS
SOPHIE SAMUEL, ADA SELINA JUTBA, HALEY PARKER, GREGORY PON, JENNIFER CORTES. Memorial Hermann Health System, Houston, TX, USA


11:18
PREDICTION OF ANTICOAGULANT-RELATED BLEEDING IN PATIENTS WITH CANCER ON PRIMARY THROMBOPROPHYLAXIS
KRISTEN M SANFILIPPO1, 2, YAN YAN1, BRIAN F GAGE1. 1Washington University in St. Louis School of Medicine, Saint Louis, MO, USA. 2St. Louis Veterans Administration Medical Center, Saint Louis, MO, USA


SHORT TALKS - DIAGNOSIS, MONITORING, AND PATIENT EXPERIENCE IN BLEEDING DISORDERS
Chair/Organizer: Bethany Samuelson Bannow, Amber Pruett
Oregon Ballroom 204


10:30
GLOBAL REACH AND CLINICAL IMPACT OF VWDTEST. COM: ADVANCING AWARENESS AND EARLY DETECTION OF VON WILLEBRAND DISEASE
FERNANDO F CORRALES-MEDINA1, 2, ROBERT F SIDONIO JR3, VERONICA FLOOD4, 5, ANA BOBAN6, 7, SUSAN HALIMEH8, MARASA TERESA A9, NATHAN T. CONNELL10, LAURA VILLARREAL-MARTASNEZ11, ALOK SRIVASTAVA12, ERIK BERNTORP13. 1Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA. 2University of Miami-Hemophilia and Thrombosis Treatment Center, Miami, FL, USA. 3Associate Professor of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA, USA. 4Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA. 5Versiti Blood Research Institute, Milwaukee, WI, USA. 6Haemophilia Center, Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia. 7Zagreb University School of Medicine, Zagreb, Croatia. 8Gerinnungszentrum Rhein-Ruhr (GZRR), Duisburg, Germany. 9La Paz University Hospital, Madrid, Spain. 10 Boston Bleeding Disorders Center, Brigham and Womena, Boston, MA, USA. 11Dr. Jose Eleuterio Gonzalez Monterrey University Hospital, Monterrey, Mexico. 12St. Johna, Bengaluru, India. 13Clinical Coagulation Research, Department of Translational Medicine, Lund University, MalmAp, Sweden


10:42
ASSESSING AND DISCUSSING PAIN IN THE HEMOPHILIA CLINIC: ACCEPTABILITY AND FEASIBILITY OF THE PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS) MEASURES OF PAIN INTENSITY, INTERFERENCE AND BEHAVIOR IN ADULT MALES WITH HEMOPHILIA
TYLER W. BUCKNER. University of Colorado School of Medicine, Aurora, CO, USA


10:54
CLINICAL DIAGNOSIS AND MANAGEMENT STRATEGIES IN PERSONS WITH BLEEDING DISORDERS OF UNKNOWN CAUSE: A SCOPING REVIEW
EVANGELINA CLARK1, LING-YI GUO1, DIANE LORENZETTI2, 3, RAFAL ASMARO4, DAWN GOODYEAR4, 5, NATALIA RYDZ4, 5, JULIA HEWS-GIRARD6, ROY KHALIFE7, 8, KELSEY UMINSKI4, 5. 1Department of Medicine, University of Calgary, Calgary, AB, Canada. 2Health Sciences Library, University of Calgary, Calgary, AB, Canada. 3Department of Community Health Sciences, Calgary, AB, Canada. 4Division of Hematology and Hematologic Malignancies, Calgary, AB, Canada. 5Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, Calgary, AB, Canada. 6Faculty of Nursing, University of Calgary, Calgary, AB, Canada. 7Ottawa Hospital Research Institute, Ottawa, ON, Canada. 8Division of Hematology, Department of Medicine, Ottawa, ON, Canada


11:06
COMPREHENSIVE COAGULATION PROFILES AND FIBRINOLYSIS ASSESSMENT AT THE POINT-OF-CARE FOR POSTPARTUM HEMORRHAGE MONITORING
DANIEL HOARE1, MICHAELA FARBER2, SEEMANTINI NADKARNI1. 1Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 2Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Womena, Boston, MA, USA


11:18
NOVEL FIBRINOLYSIS ASSAYS SHOW ALTERATIONS IN CLOT LYSIS IN ADOLESCENTS WITH HEAVY MENSTRUAL BLEEDING AND BLEEDING DISORDER OF UNKNOWN CAUSE
RUCHIKA SHARMA1, LAURA KETELBOETER2, CHAD SKAER2, MANOJ PAUL2, LINDSEY HARTLAND1, KENDRA MALONE1, CHAO XING3, SONG XHANG3, MICHAEL WU4, CHRISTIAN KASTRUP2, AYESHA ZIA1. 1Division of Hematology/Oncology/BMT, Department of Pediatrics, University of Texas Southwestern Medical Center, Children's Health Dallas, Dallas, TX, USA. 2Versiti Blood Research Institite, MIlwaukee, WI, USA. 3O'Donnell School of Public Health, UT Southwestern Medical Center, Dallas, TX, USA. 4Division of General Internal Medicine, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA


SHORT TALKS - INFLAMMATION, THROMBOSIS, AND ORGAN INJURY IN SICKLE CELL DISEASE
Chair/Organizer: Samantha Carlson, Roona Sinha
Oregon Ballroom 201


10:30
PATHOGENESIS OF FLU-INDUCED PULMONARY THROMBOSIS IN SICKLE CELL DISEASE MICE. (THSNATRAVEL AWARDEE)
TOMASZ KAMINSKI1, NICHOLAS SWENDROWSKI1, PRITHU SUNDD1, 2. 1Thrombosis and Hemostasis Program, Versiti Blood Research Institute, Milwaukee, WI, USA. 2Department of Medicine (Hematology and Oncology), Medical College of Wisconsin, Milwaukee, WI, USA


10:42
UPTAKE OF CIRCULATING DNA BY PLATELETS PROMOTES LUNG INJURY IN SICKLE CELL DISEASE(THSNATRAVEL AWARDEE)
FNU MANIKANTA1, TOMASZ W KAMINSKI1, AYYANAR SIVANANTHAM1, NICHOLAS SWENDROWSKI1, JOSHUA FIELD1, 2, SHANE HOWE1, PRITHU SUNDD1, 2. 1Versiti Blood Research Institute, Milwaukee, WI, USA. 2Medical College of Wisconsin, Milwaukee, WI, USA


10:54
RISK AND OUTCOMES OF PULMONARY EMBOLISM IN TRAUMA-ASSOCIATED HOSPITALIZATIONS AMONG INDIVIDUALS WITH SICKLE CELL DISEASE (THSNATRAVEL AWARDEE)
AYOBAMI OLAFIMIHAN1, VICTORIA OJUKWU2, LEWIS HSU3. 1John H Stroger Hospital of Cook County, Chicago, IL, USA. 2UChealth Parkview Medical Center, Pueblo, CO, USA. 3University of Illinois at Chicago, Chicago, IL, USA


11:06
TLR9 PROTMOTES NEUTROPHIL EXTRACELLULAR TRAPS GENERATION IN SICKLE CELL DISEASE(THSNATRAVEL AWARDEE)
AYYANAR SIVANANTHAM1, SHANE HOWE2, NICHOLAS SWENDROWSKI1, JOSHUA J FIELD2, 3, PRITHU SUNDD1, 4. 1Thrombosis and Hemostasis Program, Versiti Blood Research Institute and Blood Center of Wisconsin, Milwaukee, WI, USA. 2Translational Hematology Program, Versiti Blood Research Institute, Milwaukee, WI, USA. 3Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. 4Department of Biomedical Engineering, Medical College of Wisconsin, Milwaukee, WI, USA


11:18
EFFECT OF PLASMEPSIN ON VENOUS THROMBOSIS IN SICKLE CELL DISEASE
JINTAO WANG, PAUL SILAGHI, DANIEL T. EITZMAN. University of Michigan, Ann Arbor, MI, USA

11:45 - 12:45 PM
SATELLITE SYMPOSIUM
AN OVERVIEW OF VON WILLEBRAND DISEASE AND ITS TREATMENT (SPONSORED BY TAKEDA)
B110-112

Join us for our satellite symposium featuring an overview of von Willebrand Disease and its treatment. Our distinguished speaker will be Dr. Maissaa Janbain, a hematologist at the Louisiana Center for Bleeding and Clotting Disorders with clinical expertise in inherited bleeding disorders, including von Willebrand disease. Dr. Janbain is engaged in patient care and professional education focused on optimizing diagnosis and management strategies across diverse patient populations.



DIVE DEEPER: GET TO KNOW A TREATMENT OPTION FOR YOUR PATIENTS WITH HEMOPHILIA (SPONSORED BY NOVO NORDISK)
B115-116

Replacement therapy with clotting factor concentrates is the most common treatment for people with hemophilia A or hemophilia B. While there have been advances in the treatment options for people with hemophilia, there remains a need for additional prophylactic non-factor therapy options, especially for people with hemophilia B with and without inhibitors. This program will provide information on a prophylactic treatment option for people with hemophilia B and hemophilia A with and without inhibitors and share results from clinical trials.



FINE-TUNING THE COAGULATION CASCADE: HOW WE CHOOSE FROM EXPANDING OPTIONS FOR PATIENTS WITH HEMOPHILIA (SUPPORTED BY SANOFI)
B113-114

This activity is supported by an educational grant from Sanofi. This activity is provided by Integrity CE, LLC. Clinicians managing hemophilia face challenges keeping pace with rapidly evolving therapies, diverse mechanisms, and complex safety profiles. This program delivers expert-led, evidence-based education to help clinicians effectively apply new treatments, individualize therapy, and align decisions with patient goals, inhibitor status, and real-world practice needs. There are no fees for participating and receiving CME credit for this on-demand activity. During the period of April 9, 2026, to April 21, 2026, participants must visit https://integrityce. com/HemVirtual Read the learning objectives Complete the pretest Study the educational activity Complete the posttest and the evaluation form A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form. A statement of credit will be issued by our system and immediately available to download following your completion of the posttest and evaluation.


12:45 - 1:30 PM
POSTERS/EXHIBITS/BREAK
POSTERS/EXHIBITS/BREAK (click to view)
Exhibit Hall A


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION


501
PLATELET DYSFUNCTION IN PEDIATRIC PATIENTS ON THE KETOGENIC DIET
KRISTIN N. MAHER1, SUSANNA FENSTERMACHER2, NABIHA H. SAIFEE3, JASON P. LOCKROW4. 1Department of Pediatrics, Division of Hematology, Oncology, Bone Marrow Transplant and Cellular Therapy, University of Washington, Seattle, WA, USA. 2Division of Pediatric Neurology, Seattle Children's Hospital, Seattle, WA, USA. 3Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. 4Department of Neurology, University of Washington, Seattle, WA, USA


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS


503
LABORATORY VALIDATION OF TECHNOFLUOR FXIII ACTIVITY ON CEVERON S100 INSTRUMENT
RACHEL R LEGER, JULIANA PEREZ BOTERO, M. D. , DONG CHEN, M. D, PH. D. , RAJIV K PRUTHI, M. B. B. S. Mayo Clinic, Rochester, MN, USA


504
HEAT INACTIVATION OF EFANESOCTOCOG ALFA (ALTUVIIIO) IN PATIENT'S PLASMA TO ACCURATELY DETERMINE FACTOR VIII INHIBITOR TITER BY BETHESDA ASSAY.
ANDREA STAUM, ANDREW PODD, TINA AGOSTINI, GEOFFREY WOOL, BAILEY HUTCHISON, SANDRA HABERICHTER, KENNETH FRIEDMAN. Versiti, Milwaukee, WI, USA


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


505
TRANSAMINASE ELEVATIONS IN THE FITUSIRAN CLINICAL DEVELOPMENT PROGRAM WITH THE ANTITHROMBIN-BASED DOSE REGIMEN
SANJAY AHUJA1, SAVITA RANGARAJAN2, 3, CHUR-WOO YOU4, BULENT ZULFIKAR5, ABHIMANYU YARRAMANENI6, LAUREL A MENAPACE6, YUQIAN SHEN6, STEVEN W PIPE7. 1Rainbow Hemostasis a Thrombosis Center, University Hospitals Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA. 2Advanced Centre for Oncology, Haematology and Rare Diseases, K. J. Somaiya Super Specialty Hospital, Mumbai, India. 3Faculty of Medicine, University of Southampton, Southampton, United Kingdom. 4Department of Pediatrics, Eulji University School of Medicine, Daejeon, South Korea. 5Division of Pediatric Hematology-Oncology, Istanbul University Oncology Institute, Istanbul, Turkey. 6Sanofi, Cambridge, MA, USA. 7Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, USA


506
UNDERSTANDING INFORMATION ACCESS, TREATMENT DECISION-MAKING AND TREATMENT SATISFACTION AMONG CAREGIVERS OF CHILDREN WITH ≤17 YEARS OLD WITH HEMOPHILIA A OR B: PRELIMINARY FINDINGS FROM A SURVEY STUDY
POOJITA DASIKA1, JENNIFER DAVILA2. 1Albert Einstein College of Medicine, Bronx, NY, USA. 2Albert Einstein College of Medicine, Department of Pediatrics, Bronx, NY, USA


507
FROM EFFICACY TO EXPERIENCE: 52-WEEK PATIENT-REPORTED OUTCOMES WITH MIM8 IN ADOLESCENTS AND ADULTS WITH HEMOPHILIA A WITH OR WITHOUT INHIBITORS (FRONTIER2)
CACDRIC HERMANS1, SANJAY AHUJA2, HAZZA ALZAHRANI3, CIHAN AY4, PETER KAMPMANN5, SAMYA OBAJI6, SOPHIE SUSEN7, CIPRIAN IONUT TOMULEASA8, LIZE VAN VULPEN9, AMALIE RHODE HACGH NIELSEN10, ILGIZ RAKHMATULLIN10, EMILY WATERS11, CARMEN ESCURIOLA-ETTINGSHAUSEN12, ARJUN MENON11. 1Division of Hematology, Cliniques universitaires Saint-Luc, UniversitAc catholique de Louvain (UCLouvain), Brussels, Belgium. 2Department of Pediatric Hematology and Oncology, Rainbow Babies and Childrena, Cleveland, OH, USA. 3Department of Hematology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. 4Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria. 5Department of Hematology, Rigshospitalet, Copenhagen, Denmark. 6Department of Haematology, Cardiff and Vale University Health Board, Cardiff, United Kingdom. 7Hemostasis and Transfusion Department, University of Lille, Lille University Hospital, Lille, France. 8Department of Hematology, a, Cluj-Napoca, Rumania. 9Center for Benign Haematology, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands. 10Novo Nordisk A/S, SAcborg, Denmark. 11Novo Nordisk, Inc, Plainsboro, NJ, USA. 12Haemophilia Centre Rhein Main (HZRM), Frankfurt, Germany


508
PRECISION AND REPRODUCIBILITY OF A NEW AUTOMATED CHEMILUMINESCENT IMMUNOASSAY FOR THE DETECTION OF ANTI-PLATELET FACTOR 4/HEPARIN (PF4/H) IGG ANTIBODIES
NIKI LEONARD, KERRIE JASKAL. Werfen, Bedford, MA, USA


509
BLEED TREATMENT OUTCOMES FROM THE XTEND-ED STUDY IN PATIENTS AGED 50 YEARS AND OLDER
JOHANNES OLDENBURG1, BARBARA KONKLE2, TOSHKO LISSITCHKOV3, PRATIMA CHOWDARY4, LIANE KHOO5, KATSUYUKI FUTATAKE6, ELENA SANTAGOSTINO7, HELENA PALMBORG8, LINDA BYSTRICKAI7, JENNIFER DUMONT9, MEREDITH FOSTER9, SRIYA GUNAWARDENA10, ANDREW WILSON10, ANNETTE VON DRYGALSKI11, SCOTT CLELAND10. 1University Hospital Bonn, Bonn, Germany. 2Washington Center for Bleeding Disorders, University of Washington, Washington, WA, USA. 3Specialized Hospital for Active Treatment of Hematological Diseases, Department of Chemotherapy, Hemotherapy and Hereditary Blood Diseases at Clinical Hematology Clinic, Sofia, Bulgaria. 4Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom. 5Royal Prince Alfred Hospital, NSW Health Pathology, Sydney, Australia. 6Ogikubo Hospital, Tokyo, Japan. 7Sobi, Basel, Switzerland. 8Sobi, Stockholm, Sweden. 9Sanofi, Cambridge, MA, USA. 10Sanofi, Morristown, NJ, USA. 11Division of Hematology/Oncology, Department of Medicine, University of California, San Diego, CA, USA


510
TREATMENT OF ACQUIRED VON WILLEBRAND'S SYNDROME IN THE SETTING OF MONOCLONAL DYSPROTEINEMIAS
FATIMA SHABA, SERENA NAVITSKAS, ERIN AAKRE, AMANDA HERTEL, DONG CHEN, RAJIV PRUTHI, MEERA SRIDHARAN. Mayo Clinic, Rochester, MN, USA


511
LABORATORY VALIDATION OF ADAMTS-13 ANTIBODY ASSAY
MELISSA S. STUART, RAJIV K. PRUTHI, M. B. B. S, DONG CHEN, M. D, PH. D. . Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA


512
OVERVIEW ON MANAGEMENT OF BREAKTHROUGH BLEEDS AND MAJOR SURGERIES FOLLOWING BLEED MANAGEMENT GUIDELINES DURING THE FITUSIRAN CLINICAL PROGRAM IN PEOPLE WITH HEMOPHILIA
JULIAN ZORRILLA1, KAAN KAVAKLI2, LAISZLA³ NEMES3, TIENAN ZHU4, STEPHANIE P'NG5, STEVEN W PIPE6, MAREK DEMISSIE7, ABHIMANYU YARRAMANENI8, YUQIAN SHEN7, UMER KHAN7, GUY YOUNG9. 1Nemours Childrena, Jacksonville, FL, USA. 2Division of Hematology, Department of Pediatrics, Ege University Faculty of Medicine, Izmir, Turkey. 3National Haemophilia Center and Haemostasis Department, Center Hospital of Northern Pest - Military Hospital, Budapest, Hungary. 4Peking Union Medical College Hospital, Beijing, China. 5Fiona Stanley Hospital, Murdoch, Australia. 6University of Michigan Medical Center, Department of Hemophilia and Coagulation Disorders, Ann Arbor, MI, USA. 7Sanofi, Cambridge, MA, USA. 8Sanofi, Morristown, NJ, USA. 9Hemostasis and Thrombosis Center, Cancer and Blood Disease Institute, Childrena, Los Angeles, CA, USA


A8. ANTITHROMBOTIC THERAPY


514
EVALUATION OF COMPLIANCE WITH RECOMMENDATION TO TAKE RIVAROXABAN WITH FOOD
NGHI HA, ERIN MOULAND, DENISE SUTTER-LONG, ELIZABETH RENNER, ANISA BICI. Michigan Medicine, Ann Arbor, MI, USA


515
MECHANISTIC POPULATION PK/PD MODELLING OF REGN7508CAT SUPPORTS DOSE SELECTION FOR SUSTAINED FXI SUPPRESSION AND APTT RESPONSE IN HEALTHY VOLUNTEERS AND POST-SURGICAL VTE-PREVENTION PARTICIPANTS
OLEG MILBERG1, HISHAM ABDALLAH1, RACHEL KUDGUS LOKKEN2, ROBERT DINGMAN1, KAROLINE A. MEAGHER1, POULABI BANERJEE1, MICHAEL E. BURCZYNSKI1, ETHAN MARIN1, AARON KITHCART1, DAVID E. GUTSTEIN1. 1Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA. 2Allucent, Cary, NC, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


516
TRANSFORMING AF CARE: A LEARNING LAB APPROACH TO ADVANCING ANTICOAGULATION QUALITY IMPROVEMENT
GEOFFREY BARNES1, TRACY BLITHE2, AMANDA KATZ3, ELIZABETH GOLDSTEIN3, JULIE GOUVEIA-PISANO4, CHARLES J MEDICO4, BARBARA K PRITCHARD4, JULIE SIMONSON4, ANNE MARIE SMITH2. 1University of Michigan Medical School, Ann Arbor, MI, USA. 2Heart Rhythm Society, Washington, DC, USA. 3Anticoagulation Forum, Newton, MA, USA. 4Pfizer Inc, New York, NY, USA


517
CHARACTERIZING LOW MOLECULAR WEIGHT HEPARIN-ASSOCIATED BLEEDING RISK IN THROMBOLYSIS OR THROMBECTOMY FOR VENOUS THROMBOEMBOLISM
NATASHA JOLAKOSKI, LISA KOSELKE, ALLISON BURNETT. University of New Mexico Hopsital, Albuqerque, NM, USA


518
DISPARITIES IN ANTICOAGULATION PRESCRIBING ACROSS DIFFERENT RACE/ETHNICITIES
ANNJAY TABBILOS, JOE MAZUR, SIENNA MILLER, JENNIFER MAZUR, JULIE ANN EHRET, JOLI FERMO, AGNES MUSYOKA, EMILY OVERLY. Medical University of South Carolina, Charleston, SC, USA

1:30 - 2:45 PM
PLENARY SESSION
WHEN GUIDELINES HIT THE GROUND: IMPACT, IMPLICATIONS AND IMPLEMENTATION
Chair/Organizer: Leo Brandao, Roona Sinha
Oregon Ballroom 201


1:30
IMPACT OF EVIDENCE-BASED GUIDELINES
SUSAN GOODMAN.


1:55
IMPLICATIONS OF GUIDELINES FOR THROMBOSIS & HEMOSTASIS - GOOD, BAD, UGLY? MEDICINE, MONEY AND MALPRACTICE
ADAM CUKER.


2:20
IMPLEMENTATION-HOW TO TRANSLATE GUIDELINE-SUPPORTED EVIDENCE INTO PRACTICE
ANNE SALES.

3:00 - 4:30 PM
LABORATORY / BASIC SCIENCE
INNOVATIVE TECHNOLOGIES FOR CLINICAL LABORATORY PRACTICE
Chair/Organizer: Andy Goodwin, Shannon Meeks
Oregon Ballroom 204


3:00
ROLE OF TISSUE FACTOR TESTING AS A BLEEDING MODIFIER
SOL SCHULMAN.


3:30
PLATELET FUNCTION EVALUATION USING MICROFLUIDICS
NATHAN SNIADECKI.


4:00
HEMOSTASIS ON A CHIP & APP-BASED CLINICAL ASSAYS
WILBUR LAM.

3:00 - 4:30 PM
HEMOSTASIS
REDEFINING GUIDANCE ON BLEEDING DISORDERS IN SPORTS
Chair/Organizer: Caroline Kruse, Bethany Samuelson Bannow
Oregon Ballroom 203


3:00
SPORTS PARTICIPATION IN THE ERA OF INNOVATIVE THERAPIES / WHAT ARE THE CLINICAL BENEFITS OF SPORTS PARTICIPATION IN PATIENTS WITH BLEEDING DISORDERS
CLAYTON KUBRICK.


3:30
DEVELOPING A SHARED DECISION PLAN PRIOR TO TRAINING/SPORTS ACTIVITY
MICHAEL TARANTINO.


4:00
CLINICAL RISKS TO PARTICIPATING IN PHYSICAL EXERCISE AND THE RISK OF INJURY ASSOCIATED WITH PARTICULAR SPORTS/ACTIVITIES
PATRICIA LONGMUIR.

3:00 - 4:30 PM
THROMBOSIS
SPECIAL SITE, SPECIAL STRATEGY: ANTICOAGULATION IN COMPLEX VASCULAR BEDS
Chair/Organizer: Gabe Fontaine, Adam Cuker
Oregon Ballroom 201


3:00
THERAPEUTIC ANTICOAGULATION FOR ARTERIAL THROMBOSIS/REVASCULARIZATION (A DUA, MGH)
ANAHTIA DUA.


3:30
FROM THE VEINS OF LITTLE BRAINS: UPDATES AND DILEMMAS IN PEDIATRIC CEREBRAL SINUS VENOUS THROMBOSIS (CSVT)
SAMYAMI CHOWDHURY.


4:00
MOVING TO MULTIDISCIPLINARY PARADIGM OF MANAGING SPLANCHNIC VEIN THROMBOSIS
JONATHAN BERRY.

4:30 - 5:15 PM
POSTERS/EXHIBITS/BREAK
POSTERS/EXHIBITS/BREAK (click to view)
Exhibit Hall A


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS


602
ASSOCIATION OF PEAK GAMMA PRIME FIBRINOGEN LEVELS WITH OUTCOMES IN TRAUMA PATIENTS
LYDIA BUZZARD1, ALI ORAN2, MARTIN SCHREIBER3, DAVID FARRELL1. 1Donald D. Trunkey Center for Civilian and Combat Casualty Care, Department of Surgery, Oregon Health a Science University, Portland, OR, USA. 2Department of Surgery, Oregon Health a Science University, Portland, OR, USA. 3Uniformed Services University of the Health Sciences, Bethesda, MD, USA


603
RELEVANCE OF ANNEXIN V WITH COAGULATION FACTORS X AND V IN PULMONARY EMBOLISM PATIENTS
ARYAN MATHUR, MIRA NIGUDKAR, MARTIN LUNDY, FAKIHA SIDDIQUI, DEBRA HOPPENSTEADT, AMIR DARKI, JEANINE WALENGA, JAWED FAREED. Loyola University Stritch School of Medicine, Maywood, IL, USA


604
FACTOR IIA INHIBITORS: MECHANISMS, CLINICAL COMPLICATIONS, AND ADVANCES IN REVERSAL STRATEGIES
PARNIKA TANGUTURU1, FAKIHA SIDDIQUI2, JAWED FAREED2. 1Global Thrombosis Forum, Suwanee, GA, USA. 2Loyola University, Chicago, IL, USA


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


605
FITUSIRAN: A NOVEL ANTITHROMBIN-TARGETING THERAPY FOR HEMOPHILIA A AND B, WITH OR WITHOUT INHIBITORS
MOHAMMAD ALASHQAR1, MILAP NAHATA1. 2. 1Institute of Therapeutic Innovations and Outcomes, College of Pharmacy, The Ohio State University, Columbus, OH, USA. 2College of Medicine, The Ohio State University, Columbus, OH, USA


606
PREVALENCE OF SOCIAL NEEDS AND THEIR ASSOCIATION WITH HEALTHCARE UTILIZATION IN VON WILLEBRAND DISEASE
ANIKA DHINGRA1, CHENGSHI JIN1, 2, SOPHIE SHEAN3, ZAHARA JONES3, MARY LESH3, KATRINA UNPINGCO3, ALISON MATSUNAGA1, 3, SHREYA AGARWAL1, 3. 1School of Medicine, University of California San Francisco, San Francisco, CA, USA. 2Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA. 3Division of Hematology, Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA


608
FRONTIER3: SAFETY AND EFFICACY OF MIM8 PROPHYLAXIS IN PEDIATRIC PATIENTS WITH HEMOPHILIA A
JOHNNY MAHLANGU1, M. ELAINE EYSTER2, KARIN FIJN VAN DRAAT3, GILI KENET4, NITA RADHAKRISHNAN5, IRENA WOZNICA-KARCZMARZ6, RUNHUI WU7, CHUR WOO YOU8, ANDREA PARAMO FLORENCIO9, JAY JAY THAUNG ZAW9, EMILY WATERS10, MANUEL CARCAO11, NIKI PATEL10. 1Department of Molecular Medicine and Haematology, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa. 2Department of Medicine, Penn State College of Medicine, Hershey, PA, USA. 3Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Pediatric Hematology, Amsterdam, Netherlands. 4National Hemophilia Center, Sheba Medical Center, Tel HaShomer, Israel. 5Department of Pediatric Hematology Oncology, Post Graduate Institute of Child Health, Noida, India. 6Department of Transfusion Medicine, Children`s University Hospital, Lublin, Poland. 7Department of Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. 8Daejeon Eulji Medical Center, Eulji University, Daejeon, Korea. 9Novo Nordisk A/S, SAcborg, Denmark. 10Novo Nordisk, Inc, Plainsboro, NJ, USA. 11Division of Hematology/Oncology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada


609
FRONTIER5 DIRECT SWITCH STUDY: SAFETY OF INITIATING MIM8 PROPHYLAXIS WITHOUT WASHOUT OF EMICIZUMAB
JOHANNES OLDENBURG1, GARY BENSON2, PRATIMA CHOWDARY3, ROBERT KLAMROTH1, 4, ANNE LIENHART5, DAVIDE MATINO6, CAMILA MARTINS MAZINI TAVARES7, KEIJI NOGAMI8, FLORA PEYVANDI9, 10, AMALIE RHODE HACGH NIELSEN7, GUY YOUNG11, EMILY WATERS12, ALLISON P WHEELER13, ATISH PATEL12. 1Institute of Experimental Haematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany. 2Department of Haematology, Belfast Health and Social Care Trust, Belfast, United Kingdom. 3Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom. 4Vivantes Klinikum im Friedrichshain, Berlin, Germany. 5Unite d'Hemostase Clinique, Centre de Reference de l'Hemophilie, Hopital Louis Pradel, Lyon, France. 6Department of Medicine, McMaster University, Hamilton, ON, Canada. 7Novo Nordisk A/S, SAcborg, Denmark. 8Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan. 9Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, 20122, Milan, Italy. 10Department of Pathophysiology and Transplantation, UniversitAn degli Studi di Milano, Milan, Italy. 11Cancer and Blood Disease Institute, Childrena, Los Angeles, CA, USA. 12Novo Nordisk Inc, Plainsboro, NJ, USA. 13Washington Center for Bleeding Disorders, Seattle, WA, USA


610
NON-JOINT BLEEDS IN PATIENTS WITH HEMOPHILIA A OR B WITH INHIBITORS: CONCIZUMAB EXPLORER7 STUDY
AMY SHAPIRO1, ANA BOBAN2, RENACE BROWN FRANDSEN3, GIANCARLO CASTAMAN4, KINGSLEY HAMPTON5, KEIJI NOGAMI6, JAMEELA SATHAR7, SENTHIL VEL3, JERZY WINDYGA8, EMILY WATERS9, VICTOR JIMENEZ YUSTE10, ALLISON DUCHMAN9. 1Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA. 2Haemophilia Centre, Department of Haematology, University Hospital Centre Zagreb, Zagreb, Croatia and School of Medicine, University of Zagreb, Zagreb, Croatia. 3Novo Nordisk A/S, SAcborg, Denmark. 4Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy. 5Department of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom. 6Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan. 7Department of Haematology, Ampang Hospital, Kuala Lumpur, Malaysia. 8Department of Haemostasis Disorders and Internal Medicine, Laboratory of Haemostasis and Metabolic Diseases, Institute of Haematology and Transfusion Medicine, 02-776, Warsaw, Poland. 9Novo Nordisk Inc, Plainsboro, NJ, USA. 10Department of Haematology, La Paz University Hospital Coagulopathies and Disorders of Haemostasis Group IdiPaz, AutA³noma University, Madrid, Spain


611
EVALUATION OF PLASMINOGEN ACTIVATOR INHIBITOR-1 IN END-STAGE RENAL DISEASE PATIENTS
RIDDHI SURVE1, CHARVI CHEGIREDDY1, FAKIHA SIDDIQUI 2, JAWED FAREED2, VINOD BANSAL2. 1Global Thrombosis Forum, Suwanee, GA, USA. 2Loyola University, Maywood, IL, USA


A7. PATHOPHYSIOLOGY OF THROMBOSIS


612
EVALUATION OF C-REACTIVE PROTEIN IN END-STAGE RENAL DISEASE PATIENTS
NEHA KOGANTI1, AARAV GUPTA1, FAKIHA SIDDIQUI 2, JAWED FAREED2, VINOD BANSAL2. 1Global Thrombosis Forum, Suwanee, GA, USA. 2Loyola University, Maywood, IL, USA


613
ENROLLMENT CHARACTERISTICS AND REAL-WORLD INSIGHTS INTO DISEASE BURDEN AND GIVOSIRAN TREATMENT IN PATIENTS WITH ACUTE HEPATIC PORPHYRIA IN THE ELEVATE REGISTRY
ELIANE SARDH1, DAVID CASSIMAN2, LAURENT GOUYA3, BRUCE WANG4, WEIMING DU5, DESMOND MURPHY5, TERESA L. KAUF5, JAMIE L. WEISS5, MANISHA BALWANI6. 1Porphyria Centre Sweden, Centre for Inherited Metabolic Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. 2Department of Gastroenterology-Hepatology and Center for Metabolic Diseases, University Hospital Leuven, Leuven, Belgium. 3Centre FranAsais des Porphyries, Paris, France. 4University of California, San Francisco, CA, USA. 5Alnylam Pharmaceuticals, Cambridge, MA, USA. 6Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA


A8. ANTITHROMBOTIC THERAPY


614
RIVAROXABAN AS SECONDARY THROMBOPROPHYLAXIS IN PEDIATRIC PATIENTS WITH DIGESTIVE MALABSORPTION
ANGELA F JOURNELL 1, CHELSEA E. PETERS1, JESSICA MEZNARICH1, 2, SASIDHAR GOTETI1, 2. 1Primary Children's Hospital, Salt Lake City, UT, USA. 2University of Utah, Salt Lake City, UT, USA


615
EVALUATION OF APIXABAN DOSING PRACTICES FOR VTE/PE IN MEDICALLY COMPLEX PATIENTS
THALIA PADILLA KELLEY1, REBECCA PONTIUS1, AAMNA KHAN2, MARIE PIATSKI1, ERIC BLEEM1, NANCY PADILLA-LAZOS1, JAKE BERKOWITZ1, ONYEKACHI ANYA3, ROBERT NIXON1, KEVIN HUANG1, CORINNE LAVASSEUR1, JOSEPH SHATZEL1. 1Oregon Health a Science University, Portland, OR, USA. 2Hillsboro Medical Center, Portland, OR, USA. 3 Legacy Salmon Creek Medical Center, Portland, OR, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


616
REDUCED DOSE COMPARED TO STANDARD DOSE APIXABAN FOR VTE SECONDARY PREVENTION IN PATIENTS WITH ACTIVE CANCER
CLAIRE E. BURBRIDGE, TENLEY E. RYAN, AMANDA R. GILLION. Lt. Col. Luke Weathers Jr. Veterans Affairs Medical Center, Memphis, TN, USA


617
SURGERY IN THE EMICIZUMAB ERA: REAL-WORLD EVIDENCE FROM THE MID-ATLANTIC REGION
JAN G. KUHN1, ERIKA J. MARTIN1, REGINA BUTLER2, SUSAN GALLAGHER2, LISA MAIALE-HOWELL2, J. NATHAN HAGSTROM3, ELLE LEVY4, DYANNE MORRIS5, MARGY SENNETT6. 1Virginia Commonwealth University, Richmond, VA, USA. 2Children's Hospital of Philadelphia, Philadelphia, PA, USA. 3Lehigh Valley Health Network, Allentown, PA, USA. 4Childrena, Washington, DC, USA. 5University of Pennsylvania, Philadelphia, PA, USA. 6University of Virginia, Charlottesville, VA, USA


618
BRIDGING IN HIGH THROMBOEMBOLIC AND VENOUS THROMBOEMBOLISM RISK PATIENTS ON DIRECT ORAL ANTICOAGULANTS: IMPLICATIONS FOR ANTICOAGULATION STEWARDSHIP (BRAVO-HTV)
ITEA THOMALLARI1, THADDAUS R. HELLWIG1, 3, SHANNON D. WEGLEITNER1, AMANDA C. OWEN1, MICHAEL P. GULSETH1, 2. 1Sanford USD Medical Center, Sioux Falls, SD, USA. 2University of South Dakota Sanford School of Medicine, Sioux Falls, SD, USA. 3South Dakota State University College of Pharmacy, Sioux Falls, SD, USA

5:15 - 6:45 PM
THROMBOSIS / HEMOSTASIS
BETWEEN A CLOT AND A HARD PLACE- ANTICOAGULATION IN HIGH BLEED RISK POPULATION
Chair/Organizer: Allison Burnett, Gabe Fontaine
Oregon Ballroom 203


5:15
ANTICOAGULATION IN PATIENTS WITH INHERITED BLEEDING DISORDERS
KIMBERLY YOUKHANA.


5:45
BRAVERY OR BRASHNESS: RESTARTING ANTICOAGULATION IN ICH
GABE FONTAINE.


6:15
MANAGING THROMBOTIC RISK IN PATIENTS WITH LIVER DISEASE
STEPHANIE CARLIN.

5:15 - 6:45 PM
LABORATORY
KIDS ARE NOT LITTLE ADULTS: PEDIATRIC CONSIDERATIONS IN THE HEMOSTASIS/THROMBOSIS LABORATORY
Chair/Organizer: Mara Nunez, Madhvi Rajpurkar
Oregon Ballroom 204


5:15
DIAGNOSTIC STRATEGY FOR VWD MULTIDISIPLINARY COLLABORATION IN PEDIATRICS
MARA NUNEZ.


5:45
D-DIMER IN KIDS VERSUS ADULTS - HOW CAN WE IMPROVE TESTING ALGORITHMS AND LABORATORY TEST UTILIZATION?
CATHY HAYWARD.


6:15
VISCOELASTIC TESTING IN PEDIATRICS
MEERA CHITLUR.

5:15 - 6:45 PM
BASIC SCIENCE
PLATELETS AS AGENTS IN TRANSLATIONAL MEDICINE
Chair/Organizer: Anandi Krishnan, Sol Schulman
Oregon Ballroom 201


5:15
NOVEL APPROACHES TO CRYOEM OF PLATELET SURFACE PROTEINS TO CHARACTERIZE PLATELET DISORDERS
XU HAN.


5:45
BIOMECHANICS OF PLATELET CONTRACTILITY TO IMPROVE DIAGNOSIS OF BLEEDING DISORDERS
NINA SHAVER.


6:15
PLATELETS AS LIQUID BIOPSIES: MULTI-OMIC SIGNATURES IN HUMAN DISEASE
ANANDI KRISHNAN.

7:00 - 8:00 PM
SATELLITE SYMPOSIUM
CABLIVI REAL-WORLD EVIDENCE IN 1, 000+ PATIENTS: WHY EARLY INITIATION MATTERS (SPONSORED BY SANOFI)
B115-116

Timely diagnosis and prompt treatment initiation are essential for improving outcomes in patients with acquired thrombotic thrombocytopenic purpura (aTTP/iTTP). In this session, we will examine the latest real-world evidence of early treatment initiation with CABLIVI, how early therapeutic strategies influence patient outcomes, the latest updated international treatment guidelines, and highlight healthcare resource utilization data. Attendees will gain practical strategies to optimize treatment timing and enhance care for patients with aTTP/iTTP.



NAVIGATING A NEW FRONTIER IN HEMOPHILIA: EVALUATING THE UTILITY OF EVOLVING FVIIIA MIMETIC THERAPIES TO ADDRESS UNMET NEEDS (THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM NOVO NORDISK, INC. )
B113-114

This activity is jointly provided by AKH Inc, Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. Hemophilia management is entering a new era with innovative factor and nonfactor therapies. This activity explores new and emerging next-generation agents designed to overcome traditional challenges, such as inhibitor development, frequent dosing, and treatment burden. By using interactive, case-based scenarios, learners will develop the expertise needed to individualize patient selection and seamlessly integrate approved and emerging next-generation mimetics into routine practice, fostering a patient-centered approach. 1. 0 AMA PRA Category 1 Credit Register Here: https://hemophiliathsna26. eventbrite. com/